RecruitingNCT05259605

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification


Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Enrollment

1,650 participants

Start Date

Mar 21, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a large database of patients with primary brain tumors across 17 different tumor types to understand how new brain tumor classification systems relate to patient outcomes. It uses archived tumor tissue and existing brain scans rather than performing new procedures. **You may be eligible if...** - You are of legal adult age - You have been newly diagnosed or have a recurrence of one of 17 specific types of primary brain tumor - Your archived tumor tissue from surgery is available at the study site - You have available brain MRI or CT scans from the time of diagnosis - You have given your consent to participate (or your family member has given consent if you have passed away) **You may NOT be eligible if...** - Your tumor tissue from surgery is not available - You do not consent to having your data or tissue used for research Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.


Locations(42)

Innsbruck Universitaetsklinik

Innsbruck, Austria

Universitaetsklinikum Wien - AKH unikliniken

Vienna, Austria

Onze Lieve Vrouw Ziekenhuis

Aalst, Belgium

Institut Jules Bordet

Anderlecht, Belgium

Universitair Ziekenhuis Brussel

Brussels, Belgium

C.H.U. Sart-Tilman

Liège, Belgium

AZ Delta - Campus Rumbeke

Roeselare, Belgium

CHU Lyon - Hopital neurologique Pierre Wertheimer

Lyon, France

Hopital de La Timone

Marseille, France

Hopital la Pitie-Salpetriere

Paris, France

Knappschaft Krankenhaus Langendreer

Bochum, Germany

Universitaetsklinikum Bonn

Bonn, Germany

Universitaetsklinikum Koeln

Cologne, Germany

Universitaetsklinikum - Essen

Essen, Germany

University Hospital Frankfurt -Senckenberg Institute of Neurooncology

Frankfurt, Germany

Universitaetsklinikum Jena

Jena, Germany

Universitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und Radioonkologie

Leipzig, Germany

Universitaetsklinikum Regensburg

Regensburg, Germany

Diagnostic & Therapeutic Center of Athens Hygeia Hospital S.A.

Athens, Greece

Ospedale Bellaria-Bologna

Bologna, Italy

Azienda Ospedaliero-Universitaria Careggi

Florence, Italy

Istituto Neurologico Carlo Besta

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

Istituto Oncologico Veneto

Padova, Italy

IRCCS-Regina Elena National Cancer Center

Roma, Italy

Ospedale San Giovanni - Dipartimento Neuroscienze

Torino, Italy

The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

Amsterdam, Netherlands

Leiden University Medical Centre

Leiden, Netherlands

Erasmus MC

Rotterdam, Netherlands

Oslo University Hospital - Radiumhospitalet

Oslo, Norway

Centro Hospitalar Universitario Lisboa Norte - Hospital Sta. Maria

Lisbon, Portugal

Instituto Portugues de Oncologia de Lisboa Francisco Gentil - EPE

Lisbon, Portugal

Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Clinic de Barcelona

Barcelona, Spain

Hospital De La Santa Creu I Sant Pau

Barcelona, Spain

Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)

Barcelona, Spain

Hospital Duran i Reynals

L'Hospitalet de Llobregat, Spain

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland

UniversitaetsSpital Zurich - Neurology Clinic

Zurich, Switzerland

NHS Lothian - The Royal Infirmary Of Edinburgh

Edinburgh, United Kingdom

Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care

Newcastle upon Tyne, United Kingdom

Nottingham University Hospitals NHS Trust - City Hospital

Nottingham, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05259605


Related Trials